[HTML][HTML] Diagnosis and management of autoimmune hepatitis: current status and future directions

AJ Czaja - Gut and liver, 2016 - ncbi.nlm.nih.gov
Autoimmune hepatitis is characterized by autoantibodies, hypergammaglobulinemia, and
interface hepatitis on histological examination. The features lack diagnostic specificity, and …

Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside

C Kuhn, HL Weiner - Immunotherapy, 2016 - Taylor & Francis
The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20
years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune …

Neonatal Fc receptor: from immunity to therapeutics

TT Kuo, K Baker, M Yoshida, SW Qiao… - Journal of clinical …, 2010 - Springer
Abstract The neonatal Fc receptor (FcRn), also known as the Brambell receptor and
encoded by Fcgrt, is a MHC class I like molecule that functions to protect IgG and albumin …

Role of orally induced regulatory T cells in immunotherapy and tolerance

TB Bertolini, M Biswas, C Terhorst, H Daniell… - Cellular …, 2021 - Elsevier
Oral antigen administration to induce regulatory T cells (Treg) takes advantage of regulatory
mechanisms that the gastrointestinal tract utilizes to promote unresponsiveness against food …

Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice

N Sasaki, T Yamashita, M Takeda, M Shinohara… - Circulation, 2009 - Am Heart Assoc
Background—Accumulating evidence suggests that several subsets of regulatory T cells that
actively mediate immunologic tolerance play crucial roles in atherogenesis. Recently, orally …

[HTML][HTML] CD4 T cells induce a subset of MHCII-expressing microglia that attenuates Alzheimer pathology

K Mittal, E Eremenko, O Berner, Y Elyahu, I Strominger… - Iscience, 2019 - cell.com
Microglia play a key role in innate immunity in Alzheimer disease (AD), but their role as
antigen-presenting cells is as yet unclear. Here we found that amyloid β peptide (Aβ) …

Anti-CD3 clinical trials in type 1 diabetes mellitus

AG Daifotis, S Koenig, L Chatenoud, KC Herold - Clinical immunology, 2013 - Elsevier
Two humanized, anti-CD3 mAbs with reduced FcR binding, teplizumab and otelixizumab,
have been evaluated in over 1500 subjects, ages 7–45, with new and recently diagnosed …

Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes

C Mignogna, E Maddaloni, L D'Onofrio… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction Immunotherapies for type 1 diabetes mellitus (T1D) have been the focus of
intense research over the past few decades. Nevertheless, the results of clinical trials have …

Gut immune system and oral tolerance

P Castro-Sánchez, JM Martín-Villa - British journal of nutrition, 2013 - cambridge.org
Gut mucosal surfaces separate the external environment from the internal sterile
environment and so represent a first line of defence system. This barrier faces environments …

Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH

Y Ilan, K Shailubhai, A Sanyal - Clinical & Experimental …, 2018 - academic.oup.com
The immune system plays a role in the pathogenesis of non-alcoholic steatohepatitis
(NASH) underlying hepatocyte injury and fibrosis progression at all disease stages. Oral …